Maurice Perol
Overview
Explore the profile of Maurice Perol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
5446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Lena H, et al.
Front Oncol
. 2025 Mar;
15:1526931.
PMID: 40052124
Introduction: This study describes treatment and retreatment patterns and outcomes in patients in France following nivolumab as a second-line or later (2L+) treatment in locally advanced or metastatic non-small cell...
2.
Esnault C, Baschet L, Barbet V, Chenuc G, Perol M, Thokagevistk K, et al.
BMC Med Res Methodol
. 2025 Mar;
25(1):57.
PMID: 40025432
Background: Matching Adjusted Indirect Comparison (MAIC) is a statistical method used to adjust for potential biases when comparing treatment effects between separate data sources, with aggregate data in one arm,...
3.
Wespiser M, Swalduz A, Perol M
Transl Lung Cancer Res
. 2025 Feb;
14(1):1-6.
PMID: 39958226
No abstract available.
4.
Lucibello F, Gounant V, Aldea M, Duruisseaux M, Perol M, Chouaid C, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100743.
PMID: 39850629
Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, fusion-positive NSCLC. Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET...
5.
Sands J, Ahn M, Lisberg A, Cho B, Blumenschein Jr G, Shum E, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401349.
PMID: 39761483
Purpose: Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2-directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142) evaluated the safety...
6.
Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39694415
Objectives: Genomic profiling is a major component for first-line treatment decisions in patients with NSCLC and the timeliness of biomarker testing is essential to improve time to treatment initiation (TTI)...
7.
Thomas Q, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518004
Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), demonstrated superior efficacy over first-generation TKIs in the FLAURA trial, resulting in its approval as first-line therapy for metastatic non-small-cell lung cancer (NSCLC)....
8.
Ahn M, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al.
J Clin Oncol
. 2024 Sep;
43(3):260-272.
PMID: 39250535
Purpose: The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non-small cell lung cancer (NSCLC)....
9.
Yang J, Lee D, Lee J, Fan Y, de Marinis F, Iwama E, et al.
J Clin Oncol
. 2024 Aug;
42(34):4029-4039.
PMID: 39173098
Purpose: Epidermal growth factor receptor () tyrosine kinase inhibitors (TKIs) are standard first-line therapy for -mutant, metastatic non-small cell lung cancer (NSCLC); however, most patients experience disease progression. We report...
10.
Cabart M, Mourey L, Pasquier D, Schneider S, Lena H, Girard N, et al.
J Geriatr Oncol
. 2024 Jul;
15(7):101819.
PMID: 39068144
Introduction: In France, 40% of patients diagnosed with lung cancer are ≥70 years old, but these are under-represented in clinical trials. Using data from the French Epidemiological Strategy and Medical...